Ionis Licenses Alexander Disease Drug to Recordati for Global Ex-U.S. Rollout — Ionis Pharmaceuticals, Inc.

Event summary

Ionis grants Recordati exclusive rights to develop and commercialize zilganersen for Alexander disease outside the U.S. under a new license agreement.
Recordati will handle regulatory filings and commercialization globally, while Ionis retains U.S. commercial rights and leads global development.
$30 million upfront payment to Ionis, with additional milestone payments and mid-20% tiered royalties on net sales.
Zilganersen's FDA review has a PDUFA action date of September 22, 2026, with potential as the first disease-modifying treatment for Alexander disease.
Pivotal study results show statistically significant stabilization of gait speed in patients ≥5 years old.

The big picture

This deal underscores Ionis' strategy to leverage external partners for global expansion while maintaining control over high-value U.S. markets. Recordati's rare disease capabilities complement Ionis' RNA-targeted innovation, addressing a critical unmet need in Alexander disease. The $30 million upfront payment and milestone-based structure reflect the high stakes of bringing zilganersen to market as a potential first-in-class therapy.

What we're watching

Regulatory Approval: Whether zilganersen secures FDA approval by the September 22, 2026 PDUFA date and its implications for Ionis' independent U.S. launch.
Commercial Execution: How Recordati's rare disease expertise translates into successful global commercialization outside the U.S., particularly in navigating regional regulatory environments.
Pipeline Expansion: The pace at which Ionis advances its neurology portfolio, given zilganersen's potential as its first independent commercial launch in the field.